Overview

Outcome Study to Evaluate Klaricid XL® (Clarithromycin Modified Release) in Patients With Acute Exacerbation of Chronic Bronchitis

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this study was to evaluate the role of Klaricid XL (clarithromycin modified release) in the treatment of acute exacerbation of chronic bronchitis (AECB) and its impact on improving the quality of life.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Abbott
Treatments:
Clarithromycin
Criteria
Inclusion Criteria:

- Patients with acute exacerbation of chronic bronchitis who required antimicrobial
therapy and treated with Klaricid XL (clarithromycin modified release)

- Male and female patients age 35 years and older

Exclusion Criteria:

- Patients with clinical signs and symptoms suggesting pneumonia

- Patients with asthma

- Patients with any concomitant illness that may confound the interpretation of the
effect of study medication (e.g., pulmonary malignancy, congestive heart failure,
bronchiectasis, pneumothorax)

- Immunocompromised patients; however, patients receiving systemic steroids at baseline
for the treatment of chronic obstructive pulmonary disease can be enrolled

- Pregnant females

- Nursing mothers

- Patients who are allergic to clarithromycin